Publications

Cerchietti L, Navigante A, Sauri A, Palazzo F.  2000.  Hypodermoclysis for control of dehydration in terminal-stage cancer.. Int J Palliat Nurs. 6(8):370-4.

Navigante AH, Cerchietti LCA, Costantini P, Salgado H, Castro MA, Lutteral MA, Cabalar ME.  2002.  Conventional chest radiography in the initial assessment of adult cancer patients with fever and neutropenia.. Cancer Control. 9(4):346-51.

Cerchietti LCA, Navigante AH, Bonomi MR, Zaderajko MA, Menéndez PR, Pogany CE, Roth BMC.  2002.  Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma.. Cancer. 95(10):2230-6.

Cerchietti LCA, Navigante AH, Körte MW, Cohen AM, Quiroga PN, Villaamil EC, Bonomi MR, Roth BM.  2003.  Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study.. Pain. 105(1-2):265-73.

Cerchietti LCA, Navigante AH, Peluffo GD, Diament MJ, Stillitani I, Klein SA, Cabalar ME.  2004.  Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study.. J Pain Symptom Manage. 27(1):85-95.

Cerchietti LCA, Bonomi MR, Navigante AH, Castro MA, Cabalar ME, Roth BMC.  2005.  Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases.. J Neurooncol. 71(1):73-81.

Cerchietti LCA, Navigante AH, Lutteral MA, Castro MA, Kirchuk R, Bonomi M, Cabalar MEsther, Roth B, Negretti G, Sheinker B et al..  2006.  Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer.. Int J Radiat Oncol Biol Phys. 65(5):1330-7.

Cerchietti LCA, Navigante AH, Lutteral MA, Castro MA, Kirchuk R, Bonomi M, Cabalar MEsther, Roth B, Negretti G, Sheinker B et al..  2006.  Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer.. Int J Radiat Oncol Biol Phys. 65(5):1330-7.

Diament MJudith, Peluffo GDaniel, Stillitani I, Cerchietti LCarlos, Navigante A, Ranuncolo SMaris, Klein SMariana.  2006.  Inhibition of tumor progression and paraneoplastic syndrome development in a murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin.. Cancer Invest. 24(2):126-31.

Navigante AH, Cerchietti LCA, Castro MA, Lutteral MA, Cabalar ME.  2006.  Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer.. J Pain Symptom Manage. 31(1):38-47.

Cerchietti LCA, Navigante AH, Castro MA.  2007.  Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer.. Nutr Cancer. 59(1):14-20.

Bonomi M, Blanco-Savorio A, Cerchietti L, Navigante A, Castro M, Roth B, Wisnivesky JP.  2008.  Continuous hyperfractionated accelerated radiation therapy week-end less in combination with neoadjuvant chemotherapy for the treatment of stage III non-small-cell lung cancer.. Lung Cancer. 60(1):75-82.

Duy C, J Yu J, Nahar R, Swaminathan S, Kweon S-mi, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L et al..  2010.  BCL6 is critical for the development of a diverse primary B cell repertoire.. J Exp Med. 207(6):1209-21.

Navigante AH, Castro MA, Cerchietti LC.  2010.  Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated.. J Pain Symptom Manage. 39(5):820-30.

Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, DaGama EMGomes, Caldas-Lopes E, Beebe K, Perna F, Hatzi K et al..  2011.  Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.. Nat Chem Biol. 7(11):818-26.

Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, DaGama EMGomes, Caldas-Lopes E, Beebe K, Perna F, Hatzi K et al..  2011.  Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.. Nat Chem Biol. 7(11):818-26.

Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon S-mi, Nahar R, Braig M et al..  2011.  BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.. Nature. 473(7347):384-8.

Nahar R, Ramezani-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, Dovat S, Jumaa H, B Ye H, Melnick A et al..  2011.  Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC.. Blood. 118(15):4174-8.

Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R et al..  2013.  Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.. Blood. 122(16):2837-47.

Nielsen THolm, Diaz Z, Christodoulopoulos R, Charbonneau F, Qureshi S, Rousseau C, Benlimame N, Camlioglu E, Constantin AMarc, Oros KKlein et al..  2014.  Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trials.. Cancer Epidemiol Biomarkers Prev. 23(12):2688-93.

Pan H, Jiang Y, Boi M, Tabbò F, Redmond D, Nie K, Ladetto M, Chiappella A, Cerchietti L, Shaknovich R et al..  2015.  Epigenomic evolution in diffuse large B-cell lymphomas.. Nat Commun. 6:6921.

Purwada A, Jaiswal MK, Ahn H, Nojima T, Kitamura D, Gaharwar AK, Cerchietti L, Singh A.  2015.  Ex vivo engineered immune organoids for controlled germinal center reactions.. Biomaterials. 63:24-34.

Abate F, Todaro M, van der Krogt J-A, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A et al..  2015.  A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.. Leukemia. 29(6):1390-401.

Walker SR, Liu S, Xiang M, Nicolais M, Hatzi K, Giannopoulou E, Elemento O, Cerchietti L, Melnick A, Frank DA.  2015.  The transcriptional modulator BCL6 as a molecular target for breast cancer therapy.. Oncogene. 34(9):1073-82.

Dupéré-Richer D, Kinal M, Pettersson F, Emond A, M Calvo-Vidal N, Nichol JN, Guilbert C, Plourde D, Oros KKlein, Nielsen TH et al..  2016.  Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.. Leuk Lymphoma. :1-4.